Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intractable Positional Hiccups From Transdiaphragmatic Cardiac Pacemaker Leads.

Mayo Clinic proceedings·2026
Same author

A Multi-Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions.

Annals of clinical and translational neurology·2025
Same author

Consensus Recommendations for the Management of Neurosarcoidosis: A Delphi Survey of Experts Across the United States.

Neurology. Clinical practice·2025
Same author

<i>SLC29A3</i> Pathogenic Variants Resulting in Dural Based Fibroinflammatory Mass Lesions and H Syndrome Treated With Cobimetinib: A Case Report.

Neurology. Genetics·2024
Same author

Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights.

Annals of neurology·2024
Same author

Novel RAB39B loss-of-function mutation in patient with typical early-onset Parkinson's disease.

Parkinsonism & related disorders·2024
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

Mouse Models of Periventricular Leukomalacia
06:24

Mouse Models of Periventricular Leukomalacia

Published on: May 18, 2010

Progressive multifocal leukoencephalopathy.

Allen J Aksamit1

  • 1Allen J. Aksamit, MD Mayo Clinic College of Medicine, Department of Neurology, 200 First Street SW, Rochester, MN 55905, USA. aksamit@mayo.edu.

Current Treatment Options in Neurology
|June 27, 2008
PubMed
Summary
This summary is machine-generated.

Discontinuing immunosuppression is key for treating progressive multifocal leukoencephalopathy (PML) by restoring immunity to clear JC virus. Alternative treatments like HAART, cytosine arabinoside, cidofovir, mirtazapine, or risperidone may be considered based on patient specifics.

More Related Videos

Multifocal Electroretinograms
16:49

Multifocal Electroretinograms

Published on: December 4, 2011

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Related Experiment Videos

Last Updated: Jul 4, 2026

Mouse Models of Periventricular Leukomalacia
06:24

Mouse Models of Periventricular Leukomalacia

Published on: May 18, 2010

Multifocal Electroretinograms
16:49

Multifocal Electroretinograms

Published on: December 4, 2011

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Area of Science:

  • Neurovirology
  • Immunology
  • Pharmacology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a rare, often fatal demyelinating disease caused by JC virus reactivation in immunocompromised individuals.
  • Treatment strategies for PML are complex, balancing the risks of disease progression against the potential consequences of restoring host immunity.

Purpose of the Study:

  • To outline current and potential therapeutic approaches for managing PML in patients with exogenous immunosuppression.
  • To discuss the critical role of host immune reconstitution in controlling JC virus replication.

Main Methods:

  • Review of established and experimental treatments for PML.
  • Consideration of patient-specific factors, including underlying conditions (e.g., HIV/AIDS, organ transplantation, autoimmune disorders) and tolerance to therapies.
  • Evaluation of pharmacological interventions and emerging therapies.

Main Results:

  • Discontinuation of immunosuppressive therapy is the primary treatment, aiming to restore cell-mediated immunity to clear JC virus.
  • For HIV-associated PML, optimizing highly active antiretroviral therapy (HAART) is crucial.
  • Alternative treatments include intravenous cytosine arabinoside, cidofovir, and potentially mirtazapine or risperidone, with small interfering RNA (siRNA) as a future prospect.

Conclusions:

  • Restoring host immunity is central to PML treatment, though it may carry risks like organ rejection or autoimmune exacerbation.
  • Therapeutic decisions require careful consideration of individual patient status, disease severity, and treatment tolerance.
  • Further research is needed to establish the efficacy and safety of novel therapeutic agents for PML.